Sanofi

SAN.PAFranceAlso United States · SNY

26 filed reports · 997 financial concepts · 42 earnings calls · 22 media appearances

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

—

Net income

€7.85B

FY2025 · to Dec 31, 2025

up +39.7% vs €5.62B

Annual report

Operating income

€6.34B

FY2025 · to Dec 31, 2025

down −12.5% vs €7.25B

Annual report

Latest quarter or half year

Revenue

€14.4B

Q3 FY2026 · to Sep 30, 2026

up +16.2% vs €12.4B

6-K

Net income

€3.03B

Q3 FY2026 · to Sep 30, 2026

up +7.9% vs €2.81B

6-K

Operating income

€3.17B

H1 FY2026 · to Jun 30, 2026

down −15.7% vs €3.76B

Half-year report

Filed reports

26 reports · Dec 2017 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures, 335 interim figures.

Report typeReportsFactsPeriods
Half YearAMF4332Jun 2020 to Jun 2026
Annual · AMF-RFAAMF31,322Dec 2020 to Dec 2025
Interim · 6-KSEC EDGAR101,286Jun 2020 to Sep 2026
Annual · 20-FSEC EDGAR86,732Dec 2018 to Dec 2025
Annual · 20-F/ASEC EDGAR1674Dec 2017

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q36-K2026-09-302026-10-3060Open
FY2026 Q2half year2026-06-302026-07-3066Open
FY2026 Q26-K2026-06-302026-07-30278Open
FY202520-F2025-12-312026-02-171,564Open
FY2025AMF-RFA2025-12-312026-02-1795Open
FY2025AMF-RFA2025-12-312026-02-17954Open
FY2025 Q26-K2025-06-302025-10-27161Open
FY2025 Q2half year2025-06-302025-07-3149Open
FY2025 Q26-K2025-06-302025-07-3122Open
FY202420-F2024-12-312025-02-13662Open
FY2024 Q26-K2024-06-302024-07-25128Open
FY202320-F2023-12-312024-02-23827Open

Financial data

997 concepts · 10,346 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial610 concepts · 6,376 facts · Dec 2015 to Sep 2026

  • Total48 · Dec 2015 to Dec 2025
  • Provisions for pensions and other post-employment benefits39 · Dec 2015 to Dec 2025
  • Non-current liabilities related to business combinations and to non-controlling interests38 · Dec 2015 to Jun 2026
  • Current provisions and other current liabilities37 · Dec 2015 to Jun 2026
  • Inventories37 · Dec 2015 to Jun 2026
  • Noncontrolling interests37 · Dec 2015 to Sep 2026
  • Deferred tax assets36 · Dec 2015 to Jun 2026
  • Other intangible assets35 · Dec 2015 to Dec 2025
  • Number of shares (in shares)34 · Dec 2015 to Jun 2026
  • % of share capital for the period34 · Dec 2015 to Jun 2026
  • Cash and cash equivalents33 · Dec 2015 to Jun 2026
  • Equity33 · Dec 2015 to Jun 2026
  • Noncurrent provisions (IFRS)33 · Dec 2015 to Jun 2026
  • Assets (IFRS)32 · Dec 2015 to Jun 2026
  • Borrowings32 · Dec 2015 to Jun 2026
  • Contingent liabilities recognised in business combination32 · Dec 2015 to Jun 2026
  • Current borrowings and current portion of noncurrent borrowings (IFRS)32 · Dec 2015 to Jun 2026
  • Current liabilities related to business combinations and to non-controlling interests32 · Dec 2015 to Jun 2026
  • Current trade receivables32 · Dec 2015 to Jun 2026
  • Deferred tax liabilities (IFRS)32 · Dec 2015 to Jun 2026
  • Derecognized receivables32 · Dec 2015 to Jun 2026
  • Equity and liabilities32 · Dec 2015 to Jun 2026
  • Equity attributable to owners of parent (IFRS)32 · Dec 2015 to Jun 2026
  • Goodwill (IFRS)32 · Dec 2015 to Jun 2026

Segment69 concepts · 2,078 facts · Dec 2015 to Jun 2026

  • Revenue from sale of goods (IFRS)1,326 · Dec 2015 to Dec 2025
  • Revenue from Sale of Goods145 · Dec 2024 to Dec 2025
  • Pharmaceuticals62 · Dec 2015 to Dec 2025
  • R&D Expense40 · Dec 2019 to Jun 2026
  • Additions other than through business combinations property plant and equipment38 · Dec 2015 to Dec 2025
  • Cost of Revenue38 · Dec 2019 to Jun 2026
  • Cost of sales29 · Dec 2018 to Dec 2025
  • Other revenue (IFRS)29 · Dec 2018 to Dec 2025
  • Profit loss attributable to noncontrolling interests29 · Dec 2018 to Dec 2025
  • Research and development expense (IFRS)29 · Dec 2018 to Dec 2025
  • Selling general and administrative expense (IFRS)29 · Dec 2018 to Dec 2025
  • Share of profit loss of associates and joint ventures accounted for using equity method29 · Dec 2018 to Dec 2025
  • Purchase of intangible assets classified as investing activities23 · Dec 2018 to Dec 2025
  • Purchase of property plant and equipment classified as investing activities23 · Dec 2018 to Dec 2025
  • Goodwill20 · Dec 2017 to Dec 2023
  • Biopharma Segment12 · Dec 2022 to Dec 2025
  • Intangible Assets (excluding Goodwill)12 · Dec 2024 to Dec 2025
  • Property, Plant & Equipment, Net12 · Dec 2024 to Dec 2025
  • SG&A Expense12 · Jun 2024 to Jun 2026
  • Other Revenue11 · Dec 2024 to Jun 2026
  • Net Income Attributable to Noncontrolling Interests9 · Jun 2024 to Jun 2026
  • États-Unis6 · Jun 2020 to Jun 2026
  • Share of Profit of Associates and Joint Ventures6 · Dec 2024 to Dec 2025
  • Capital Expenditures5 · Jun 2024 to Jun 2026

IFRS295 concepts · 1,348 facts · Dec 2019 to Jun 2026

  • Intangible Assets (excluding Goodwill)48 · Dec 2019 to Dec 2025
  • Cash and Equivalents45 · Dec 2019 to Dec 2025
  • Property, Plant & Equipment, Net38 · Dec 2019 to Dec 2025
  • Stockholders Equity38 · Dec 2019 to Dec 2025
  • Total Borrowings33 · Dec 2024 to Dec 2025
  • Net Income30 · Dec 2019 to Jun 2026
  • Other Comprehensive Income28 · Dec 2019 to Dec 2025
  • Total Comprehensive Income28 · Dec 2019 to Dec 2025
  • Equity Change: Exercise of Options26 · Dec 2019 to Dec 2025
  • Other Intangible Assets (IFRS Line Item)25 · May 2024 to Dec 2025
  • Dividends Recognised as Distributions to Owners of Parent24 · Dec 2019 to Dec 2025
  • Equity Change: Purchase of Treasury Shares24 · Dec 2019 to Dec 2025
  • Dividends Recognised as Distributions to Noncontrolling Interests22 · Dec 2019 to Dec 2025
  • Equity Change: Ownership Changes Without Loss of Control22 · Dec 2019 to Dec 2025
  • Bank Overdrafts (Cash Equivalents)18 · Dec 2024 to Dec 2025
  • Reduction of Issued Capital18 · Dec 2024 to Dec 2025
  • Miscellaneous Other Operating Expense16 · Dec 2019 to Dec 2025
  • Noncurrent Provisions12 · Dec 2024 to Dec 2025
  • R&D Expense11 · Dec 2019 to Jun 2026
  • Total Lease Liabilities11 · Jun 2021 to Dec 2025
  • Investments in Joint Ventures10 · Dec 2024 to Dec 2025
  • Miscellaneous Other Operating Income10 · Dec 2019 to Dec 2025
  • Other Financing Cash Flows10 · Dec 2024 to Dec 2025
  • Accounts Receivable, Net9 · Dec 2019 to Dec 2025

Geography16 concepts · 528 facts · Dec 2015 to Jun 2026

  • Property, Plant & Equipment, Net119 · Dec 2016 to Jun 2026
  • Revenue from sale of goods (IFRS)96 · Dec 2015 to Dec 2025
  • Intangible Assets (excluding Goodwill)75 · Dec 2016 to Jun 2026
  • France51 · Dec 2015 to Dec 2025
  • Actuarial gains losses arising from changes in financial assumptions net defined benefit liability asset44 · Dec 2015 to Dec 2025
  • Gain loss on remeasurement of net defined benefit liability asset44 · Dec 2015 to Dec 2025
  • Actuarial gains losses arising from changes in demographic assumptions net defined benefit liability asset41 · Dec 2015 to Dec 2025
  • UK16 · Dec 2017 to Dec 2025
  • Weighted average duration of defined benefit obligation16 · Dec 2015 to Dec 2018
  • United States12 · Dec 2017 to Dec 2025
  • Goodwill5 · Jun 2019 to Jun 2025
  • Payments for premiums and claims annuities and other policy benefits3 · Dec 2015 to Dec 2017
  • Net foreign exchange loss2 · Dec 2016 to Dec 2018
  • Termination benefit payments2 · Dec 2018
  • Clariant retained liabilities - specially chemicals business1 · Dec 2017
  • Percentage of entitys revenue1 · Dec 2022

Product5 concepts · 12 facts · Dec 2020 to Dec 2025

  • Proceeds from disposals of property plant and equipment intangible assets other than goodwill investment property and other noncurrent assets6 · Dec 2020 to Dec 2024
  • ELOCTATE2 · Dec 2022
  • Other intangible assets2 · Dec 2024 to Dec 2025
  • Impairment loss recognised in profit or loss intangible assets other than goodwill1 · Dec 2022
  • Reversal of impairment loss recognised in profit or loss intangible assets other than goodwill1 · Dec 2022

Guidance2 concepts · 4 facts · Oct 2021 to Oct 2026

  • Effective Tax Rate Guidance2 · Oct 2026
  • EPS (Diluted) Growth Guidance2 · Oct 2021

Segments

3,255 facts

Figures broken down by business line, region, product or another axis the company reports on.

Segments19 members · 1,849 facts

  • Pharmaceuticals607 · Dec 2015 to Dec 2022
  • Biopharma553 · Dec 2021 to Dec 2025
  • Consumer Healthcare269 · Dec 2015 to Dec 2023
  • Vaccines145 · Dec 2015 to Dec 2022
  • All Other Segments72 · Dec 2018 to Dec 2025
  • Biopharma segment70 · Jun 2022 to Jun 2026
  • All other segments33 · Jun 2020 to Jun 2026
  • Reportable segments28 · Dec 2019 to Dec 2025
  • Opella13 · Dec 2023 to Dec 2024
  • Consumer healthcare segment13 · Dec 2017 to Dec 2023
  • Animal Health Business11 · Dec 2015 to Dec 2018
  • Pharmaceuticals6 · Dec 2017 to Dec 2022
  • Vaccines6 · Dec 2017 to Dec 2022
  • Vaccines segment6 · Jun 2020 to Jun 2022
  • Opella Business5 · Dec 2021 to Dec 2025
  • Pharmaceuticals segment5 · Jun 2020 to Jun 2022
  • Opella4 · Jun 2023 to Jun 2024
  • Libtayo2 · Dec 2022
  • OPALJV Co1 · Dec 2025

Geographical areasifrs-full:GeographicalAreasAxis29 members · 528 facts

  • US71 · Dec 2015 to Dec 2025
  • FR69 · Dec 2015 to Dec 2025
  • GB63 · Dec 2015 to Dec 2025
  • DE46 · Dec 2015 to Dec 2025
  • Us35 · Dec 2016 to Jun 2026
  • Other countries30 · Dec 2016 to Dec 2025
  • Fr25 · Dec 2016 to Jun 2026
  • Other countries excluding europe and north america22 · Jun 2021 to Jun 2026
  • Europe18 · Dec 2016 to Dec 2025
  • Reportable geographical zones17 · Jun 2019 to Jun 2025
  • Europe16 · Dec 2015 to Dec 2025
  • North america14 · Dec 2016 to Dec 2023
  • Europe112 · Dec 2018 to Dec 2020
  • North america112 · Dec 2018 to Dec 2020
  • North America11 · Dec 2015 to Dec 2023
  • Other Countries11 · Dec 2015 to Dec 2025
  • Reportable Geographical Zones11 · Dec 2015 to Dec 2025
  • Europe8 · Dec 2024 to Jun 2026
  • Cn6 · Dec 2024 to Jun 2026
  • Other Countries In Segment Results6 · Dec 2018 to Dec 2023
  • Europe15 · Dec 2017 to Dec 2020
  • North America14 · Dec 2017 to Dec 2020
  • RU4 · Dec 2020 to Dec 2022
  • CN3 · Dec 2023 to Dec 2025
  • Other Countries Excluding Europe And North America3 · Dec 2021 to Dec 2023
  • Other Countries In Segement Results3 · Dec 2017 to Dec 2019
  • AR1 · Dec 2018
  • Germany1 · Dec 2017
  • VE1 · Dec 2016

Components of equity9 members · 229 facts

  • Equity attributable to owners of parent37 · Dec 2019 to Dec 2025
  • Retained earnings32 · Dec 2019 to Dec 2025
  • Noncontrolling interests31 · Dec 2019 to Dec 2025
  • Accumulated other comprehensive income28 · Dec 2019 to Dec 2025
  • Treasury shares25 · Dec 2019 to Dec 2025
  • Additional paidin capital24 · Dec 2019 to Dec 2025
  • Issued capital24 · Dec 2019 to Dec 2025
  • Reserve of sharebased payments22 · Dec 2019 to Dec 2025
  • Reserve of exchange differences on translation6 · Dec 2024 to Dec 2025

Geographical areasifrs-full:GeographicalAreasAxis7 members · 132 facts

  • Us38 · Dec 2024 to Dec 2025
  • Europe38 · Dec 2024 to Dec 2025
  • Other countries in segment results32 · Dec 2024 to Dec 2025
  • Cn6 · Dec 2024 to Dec 2025
  • Fr6 · Dec 2024 to Dec 2025
  • Other countries6 · Dec 2024 to Dec 2025
  • Reportable geographical zones6 · Dec 2024 to Dec 2025

Carrying amount accumulated depreciation amortisation and impairment and gross carrying amount4 members · 68 facts

  • Gross carrying amount34 · Dec 2024 to Dec 2025
  • Accumulated depreciation amortisation and impairment30 · Dec 2024 to Dec 2025
  • Allowance for credit losses2 · Dec 2024 to Dec 2025
  • Write down2 · Dec 2024 to Dec 2025

Business line pharmacy and geography3 members · 54 facts

  • États-Unis19 · Jun 2020 to Jun 2026
  • Europe18 · Jun 2020 to Jun 2026
  • Autres pays17 · Jun 2020

Maturity8 members · 51 facts

  • Not later than one year10 · Dec 2024 to Dec 2025
  • Later than five years9 · Dec 2024 to Dec 2025
  • Later than four years and not later than five years7 · Dec 2024 to Dec 2025
  • Later than one year and not later than two years7 · Dec 2024 to Dec 2025
  • Later than three years and not later than four years7 · Dec 2024 to Dec 2025
  • Later than two years and not later than three years7 · Dec 2024 to Dec 2025
  • Later than one year and not later than three years2 · Dec 2024 to Dec 2025
  • Later than three years and not later than five years2 · Dec 2024 to Dec 2025

Classes of assets8 members · 38 facts

  • Longterm borrowings10 · Dec 2024 to Dec 2025
  • Increase decrease interest rate and currency derivatives used to manage debt10 · Dec 2024 to Dec 2025
  • Short term debt and current portion of long term debt10 · Dec 2024 to Dec 2025
  • Current assets2 · Dec 2024 to Dec 2025
  • Non current assets2 · Dec 2024 to Dec 2025
  • Securities quoted in an active market2 · Dec 2019
  • Commercial paper program in usa1 · Dec 2025
  • Contingent consideration relating to divestments1 · Dec 2020

Hedging instruments9 members · 37 facts

  • Currency derivatives financial6 · Dec 2025
  • Currency derivatives6 · Dec 2025
  • Currency derivatives operating6 · Dec 2025
  • Equity derivatives6 · Dec 2025
  • Interest rate derivatives6 · Dec 2025
  • Cross currency swap3 · Dec 2025
  • Forward currency sales in usdollar2 · Dec 2025
  • Forward currency purchased in usdollar usbond1 · Dec 2025
  • Forward currency purchases in usdollar usbond1 · Dec 2025

Classes of intangible assets other than goodwill18 members · 34 facts

  • Computer software2 · Dec 2024 to Dec 2025
  • Acquired rd2 · Dec 2024 to Dec 2025
  • Marketed products2 · Dec 2024 to Dec 2025
  • Marketed products trademarks and other rights2 · Dec 2024 to Dec 2025
  • Principal marketed products ablynx2 · Dec 2024 to Dec 2025
  • Principal marketed products ayvakit2 · Dec 2024 to Dec 2025
  • Principal marketed products beyfortus2 · Dec 2024 to Dec 2025
  • Principal marketed products bioverativ2 · Dec 2024 to Dec 2025
  • Principal marketed products boehringeringelheim consumer healthcare2 · Dec 2024 to Dec 2025
  • Principal marketed products chattem2 · Dec 2024 to Dec 2025
  • Principal marketed products protein sciences2 · Dec 2024 to Dec 2025
  • Principal marketed products qunol2 · Dec 2024 to Dec 2025
  • Principal marketed products rezurock2 · Dec 2024 to Dec 2025
  • Principal marketed products tzield2 · Dec 2024 to Dec 2025
  • Principal marketed products wayrilz2 · Dec 2024 to Dec 2025
  • Technological platforms2 · Dec 2024 to Dec 2025
  • Principal marketed products aventis1 · Dec 2024
  • Principal marketed products genzyme1 · Dec 2024

Measurement6 members · 31 facts

  • Value on redemption10 · Dec 2024 to Dec 2025
  • Value on redemption after derivative instruments8 · Dec 2024 to Dec 2025
  • Adjustment to debt measured at fair value4 · Dec 2025
  • Amortized cost4 · Dec 2025
  • Value on redemption before derivative instruments3 · Dec 2025
  • At market value2 · Dec 2024 to Dec 2025

Significant investments in subsidiaries6 members · 19 facts

  • Opella business11 · Dec 2024 to Dec 2025
  • Others4 · Dec 2024 to Dec 2025
  • Ablynx1 · Dec 2025
  • Bioverativ1 · Dec 2025
  • Blueprint medicines netherlands b.v.1 · Dec 2025
  • Principia biopharma inc1 · Dec 2025

Business activity1 member · 15 facts

  • Biopharma15 · Jun 2025 to Jun 2026

Defined benefit plans1 member · 14 facts

  • Pensions and other post employment benefits14 · Dec 2024 to Dec 2025

Significant investments in associates6 members · 14 facts

  • Regeneron4 · Dec 2024 to Dec 2025
  • Opaljvco3 · Dec 2024 to Dec 2025
  • Aggregated individually immaterial associates2 · Dec 2024 to Dec 2025
  • Associates2 · Dec 2024 to Dec 2025
  • Euroapi2 · Dec 2024 to Dec 2025
  • Regeneron pharmaceuticals inc1 · Dec 2024

Geography3 members · 13 facts

  • Vaccines7 · Jun 2021
  • Consumer Healthcare4 · Jun 2021
  • Reste du Monde2 · Jun 2020 to Jun 2026

Operating segment1 member · 11 facts

  • Autres11 · Jun 2020 to Jun 2026

Business combinations7 members · 10 facts

  • Blueprint medicines corporation2 · Dec 2025
  • Opella business2 · Dec 2024 to Dec 2025
  • Opella business2 · Dec 2024 to Dec 2025
  • Provention bio inc1 · Dec 2024
  • Qribintermediate holdings llc1 · Dec 2024
  • Vicebio ltd1 · Dec 2025
  • Vigil neurosciences1 · Dec 2025

Classes of property plant and equipment5 members · 10 facts

  • Buildings2 · Dec 2024 to Dec 2025
  • Fixtures and fittings2 · Dec 2024 to Dec 2025
  • Land2 · Dec 2024 to Dec 2025
  • Machinery and equipment12 · Dec 2024 to Dec 2025
  • Property plant and equipment in process2 · Dec 2024 to Dec 2025

Classes of provisions4 members · 10 facts

  • Provisions for pensions and other post employment benefits4 · Dec 2024 to Dec 2025
  • Miscellaneous other provisions2 · Dec 2024 to Dec 2025
  • Non current restructuring provision2 · Dec 2024 to Dec 2025
  • Provisions for other long term benefits2 · Dec 2024 to Dec 2025

Expense categories1 member · 10 facts

  • Amortization of computer software and other rights of an industrial or operational nature10 · Dec 2024 to Dec 2025

Product or service8 members · 10 facts

  • Eloctate2 · Dec 2022
  • Pharmaceuticals2 · Dec 2020 to Dec 2021
  • ALTUVIIIO1 · Dec 2022
  • Biopharma1 · Dec 2024
  • Consumer Healthcare1 · Dec 2021
  • Enjaymo Global Rights1 · Dec 2024
  • Seprafilm1 · Dec 2020
  • Tolebrutinib1 · Dec 2025

Classes of liabilities2 members · 8 facts

  • Current liabilities4 · Dec 2024 to Dec 2025
  • Non current liabilities4 · Dec 2024 to Dec 2025

Counterparties3 members · 8 facts

  • Swedish orphan biovitrum ab4 · Dec 2025
  • Regeneron pharmaceuticals inc3 · Dec 2024 to Dec 2025
  • Astra zeneca1 · Dec 2025

Joint ventures4 members · 8 facts

  • Aggregated individually immaterial associates2 · Dec 2024 to Dec 2025
  • Joint ventures2 · Dec 2024 to Dec 2025
  • Infraserv gmbh and co hochst kg2 · Dec 2024 to Dec 2025
  • Mspvaccine company2 · Dec 2024 to Dec 2025

Segment consolidation items1 member · 6 facts

  • Material reconciling items6 · Dec 2024 to Dec 2025

Income statement location13 members · 6 facts

  • Commercialization related expenses2 · Dec 2024 to Dec 2025
  • Share of profit or loss from commercialization of monoclonal antibodies2 · Dec 2024 to Dec 2025
  • Share of profit or loss from commercialization of zaltrap2 · Dec 2024 to Dec 2025

Geography and product1 member · 4 facts

  • Pharmaceuticals4 · Jun 2021

Categories of related parties1 member · 4 facts

  • Other related parties4 · Dec 2024 to Dec 2025

Classes of financial assets2 members · 4 facts

  • Cash flow and fair value hedge2 · Dec 2024 to Dec 2025
  • Foreign currency translation2 · Dec 2024 to Dec 2025

Products and servicesifrs-full:ProductsAndServicesAxis4 members · 4 facts

  • Enjaymo global rights1 · Dec 2025
  • Enjaymo global rights1 · Dec 2024
  • Pharmaceuticals1 · Dec 2020
  • Seprafilm1 · Dec 2020

Temporary difference unused tax losses and unused tax credits2 members · 4 facts

  • Deferred tax relating to capitalisation of rdexpenses2 · Dec 2024 to Dec 2025
  • Deferred tax relating to restructuring provisions2 · Dec 2024 to Dec 2025

Assets acquisition2 members · 3 facts

  • Assets acquisition2 · May 2024 to Dec 2025
  • Blueprint medicines corporation1 · Dec 2025

Classes of intangible assets and goodwill1 member · 2 facts

  • Goodwill2 · Dec 2024 to Dec 2025

Net defined benefit liability asset1 member · 2 facts

  • Uncertainties over income tax treatments2 · Dec 2024 to Dec 2025

Products and servicesifrs-full:ProductsAndServicesAxis2 members · 2 facts

  • Eloctate1 · Dec 2022
  • Enjaymo Global Rights1 · Dec 2024

Counterparty name1 member · 2 facts

  • Antibodies alliance2 · Dec 2024 to Dec 2025

Nonadjusting events after reporting period1 member · 1 fact

  • Major collaboration agreement1 · Nov 2024

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Management discussion (MD&A) commentary30 claims from 2 reports · Dec 2024 to Dec 2025
  • Risk-factor changes74 claims from 7 reports · Dec 2019 to Dec 2025
  • Risk factors200 risks from 8 annual reports · 2018 to 2025

Earnings calls

42 calls · Jul 2016 to Oct 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-10-30
  • FY2026 Q22026-07-30
  • FY2026 Q12026-04-23
  • FY2025 Q42026-01-29
  • FY2025 Q32025-10-24
  • FY2025 Q22025-07-31
  • FY2025 Q12025-04-25
  • FY2024 Q42025-01-30
  • FY2024 Q32024-10-25
  • FY2024 Q22024-07-25
  • FY2024 Q12024-04-25
  • FY2023 Q42024-02-01
  • FY2023 Q32023-10-27
  • FY2023 Q22023-07-28
  • FY2023 Q12023-04-27
  • FY2022 Q42023-02-03

Executive media

22 appearances

Podcasts, interviews and conference appearances by the company's executives, with their claims.

  • TV interviews18 · Jan 2020 to Jan 2026
  • Other appearances2 · Nov 2021 to Jul 2024
  • Conference talks1 · Dec 2025
  • Podcasts1 · Feb 2024

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Sanofi (SAN.PA) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

Sanofi (SAN.PA): FY2025 net income €7.85B · FactIQ